To begin studying our drug combinations, we selected prostate cancer cell lines with different AR genetic backgrounds that also express SRC kinase (Figure 1A), expecting a myriad of responses that will allow us to evaluate synergy between our selected drugs. This evidence concerns the gene AR and prostate cancer.